The A2 Milk Company Limited

A2M

The a2 Milk Co. Ltd. engages in the distribution and sale of milk and dairy products. The firm operates through four segments: Australia and New Zealand, China and Other Asia, USA and Mataura Valley Milk. The Australia and New Zealand segment includes the sale of infant formula, milk and other dairy products, along with royalty, license fees and rental income. The China and Other Asia segment includes the sale of infant formula, milk and other dairy products. The USA segment includes the sale of milk and license fees. The Mataura Valley Milk segment is engaged in manufacturing and sale of nutritional and commodity products. Its product portfolio is divided into three core categories: liquid milk, infant milk formula and macro milk. The company offers its products under a2 Milk and a2 Platinum brands. Its product includes a2 Milk Lite, a2 Milk Blue, a2 Platinum Premium toddler milk drink and others.

Imugene Limited

IMU

Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The company is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.

Global X Robo Global Robotics & Automation ETF

ROBO

ROBO.AX was created on 2017-09-13 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the ROBO.AX Global Robotics and Automation Index (the Index)

VanEck MSCI International Sustainable Equity ETF

ESGI

ESGI.AX was created on 2018-03-06 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide investment returns before fees and other costs which track the performance of its Reference Index in Australian dollars.

iShares Global Healthcare ETF

IXJ

IXJ.AX was created on 2001-11-13 by iShares. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of global biotechnology, healthcare, medical equipment and pharmaceuticals companies and may include large-, mid- or smallcapitalisation stocks